AAPS PharmSciTech

, Volume 12, Issue 4, pp 1056–1063 | Cite as

Synthesis of Monomethoxypolyethyleneglycol—Cholesteryl Ester and Effect of its Incorporation in Liposomes

Research Article


The objective of the present study was to synthesize monomethoxypolyethyleneglycol-5000 cholesteryl ester [PEG–CH] as a cost-effective substitute for polyethyleneglycol–phosphatidylethanolamine and to evaluate the influence of its incorporation in liposomal bilayers for surface modification. PEG–CH was synthesized and characterized by infrared (IR), proton nuclear magnetic resonance spectroscopy (1H NMR), and differential scanning calorimetry (DSC) studies. Influence of incorporation of PEG–CH in liposomes was evaluated on various parameters such as zeta potential, DSC, and encapsulation efficiency of a hydrophilic drug pentoxyfylline. Conventional and PEG–CH containing pentoxyfylline liposomes were formulated and their stability was evaluated at 4°C for 3 months. PEG–CH could be successfully synthesized with good yields and the structure was confirmed by IR, DSC, and 1H NMR. The incorporation of PEG–CH in liposomes resulted in reduction of the zeta potential and broadening of the DSC endotherm. Furthermore, incorporation of PEG–CH in liposomes decreased the encapsulation efficiency of pentoxifylline in liposomes when compared to conventional liposomes. Conventional and PEG–CH containing pentoxyfylline liposomes did not show any signs of pentoxyfylline degradation when stored at 4°C for 3 months.


liposomes PEG–cholesteryl ester steric stabilization 



Vinayak P. Sant is thankful to CSIR, New Delhi for the award of Senior Research Fellowship. Authors acknowledge the help of Dr. Krishna Iyer and Dr. Abhijit Date for manuscript preparation and useful discussions. The kind help of Phospholipid GmBH, Germany and Sun Pharmaceuticals, India is also gratefully acknowledged.


  1. 1.
    Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4:297–305.PubMedCrossRefGoogle Scholar
  2. 2.
    Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743.PubMedGoogle Scholar
  3. 3.
    Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci. 2008;97:4696–740.PubMedCrossRefGoogle Scholar
  4. 4.
    Torchillin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Rev Drug Disc. 2005;4:145–60.CrossRefGoogle Scholar
  5. 5.
    Schiffelers RM, Storm G. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. Int J Pharm. 2008;364:258–64.PubMedCrossRefGoogle Scholar
  6. 6.
    Allen TM, Sapra P, Moase E, Moreira J, Iden D. Adventures in targeting. J Liposome Res. 2002;12:5–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Ceh B, Winterhalter M, Frederik PM, Vallner JJ, Lasic DD. Stealth® liposomes: from theory to product. Adv Drug Del Rev. 1997;24:165–77.CrossRefGoogle Scholar
  8. 8.
    Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1:297–315.PubMedCrossRefGoogle Scholar
  9. 9.
    Carrion C, Domingo JC, de Madariaga MA. Preparation of long-circulating immunoliposomes using PEG–cholesterol conjugates: effect of the spacer arm between PEG and cholesterol on liposomal characteristics. Chem Phys Lipids. 2001;113:97–110.PubMedCrossRefGoogle Scholar
  10. 10.
    Semple SC, Chonn A, Cullis PR. Influence of cholesterol on the association of plasma proteins with liposomes. Biochemistry. 1996;35:2521–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Schneider T, Sachse A, Leike J, Roβling G, Schmidtgen M, Drechsler M, et al. Surface modification of continuously extruded contrast carrying liposomes: effect on their physical properties. Int J Pharm. 1996;132:9–21.CrossRefGoogle Scholar
  12. 12.
    Ishiwata H, Vertut-Doi A, Hirose T, Miyajima K. Physical chemistry characteristics and biodistribution of poly(ethyleneglycol)-coated liposomes using poly(oxyethylene)-cholesteryl ether. Chem Pharm Bull. 1995;43:1005–11.PubMedGoogle Scholar
  13. 13.
    Ishiwata H, Sato SB, Kobayashi S, Oku M, Vertut-Doi A, Miyajima K. Poly(ethylene glycol) derivative of cholesterol reduces binding step of liposome uptake by murine macrophage-like cell line J774 and human hepatoma cell line HepG2. Chem Pharm Bull. 1998;46:1907–13.PubMedGoogle Scholar
  14. 14.
    Beugin-Deroo S, Ollivon M, Lesieur S. Bilayer stability and impermeability of nonionic surfactant vesicles sterically stabilized by PEG–cholesterol conjugates. J Colloid Interf Sci. 1998;202:324–33.CrossRefGoogle Scholar
  15. 15.
    Dan-Bo Y, Jia-Bi Z, Zhang-Jian H, Hai-Xia R, Zeng-Juan Z. Synthesis and application of poly(ethylene glycol)–cholesterol (Chol–PEGm) conjugates in physicochemical characterization of nonionic surfactant vesicles. Coll Surf B. 2008;63:192–9.CrossRefGoogle Scholar
  16. 16.
    Lele BS, Kulkarni MG. Single step room temperature oxidation of poly(ethyleneglycol) to poly(oxyethylene)-dicarboxylic acids. J Appl Polymer Sci. 1998;70:883–90.CrossRefGoogle Scholar
  17. 17.
    Taylor KMG, Taylor G, Kellaway IW, Stevens J. Drug entrapment and release from multilamellar and reverse-phase evaporation liposomes. Int J Pharm. 1990;58:49–55.CrossRefGoogle Scholar
  18. 18.
    Sant VP, Paradkar AR, Nagarsenker MS. Optimization of pentoxifylline liposomes using 24 factorial design. Ind J Pharm Sci. 2002;64:459–64.Google Scholar
  19. 19.
    Dadashzadeh S, Vali AM, Rezaie M. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Int J Pharm. 2008;53:251–9.CrossRefGoogle Scholar
  20. 20.
    Lim LY, Go ML. The antimalarial agent halofantrine perturbs phosphatidylcholine and phosphatidylethanolamine bilayers: a differential scanning calorimetric study. Chem Pharm Bull. 1999;47:732–7.PubMedGoogle Scholar
  21. 21.
    Bedu-Addo FK, Tang P, Xu Y, Huang L. Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol–phospholipid conjugates with phospholipid: implications in liposomal drug delivery. Pharm Res. 1996;13:710–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Bedu-Addo FK, Tang P, Xu Y, Huang L. Interaction of polyethyleneglycol–phospholipid conjugates with cholesterol–phosphatidylcholine mixtures: sterically stabilized liposome formulations. Pharm Res. 1996;13:718–24.PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2011

Authors and Affiliations

  1. 1.Department of Pharmaceutics, Bombay College of PharmacyMumbaiIndia

Personalised recommendations